Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 28 November 2016 | By Zachary Brennan
Earlier this month, the US Food and Drug Administration (FDA) released a letter sent to Dr. PRP America for claims made on its website for an unapproved medical device that the San Diego-based company claims can help concentrate and extract blood platelets, as well as adjust blood plasma levels.
Mary Malarkey, director of the Office of Compliance and Biologics Quality at FDA’s Center for Biologics Evaluation and Research, wrote in the letter that a review of FDA’s databases found the company has not obtained approval or clearance for its Dr. PRP Kit used with or without the PRP Centrifuge.
According to the company’s website, the PRP Kit costs $85 and the centrifuge costs $2,199.
FDA says the website makes a number of claims that have not been reviewed by FDA and indicates the devices may be used for a variety of purposes, including the treatment of musculoskeletal injuries and tissue regeneration and rejuvenation.
“The Dr. PRP Kit whether sold with or without the PRP Centrifuge appears to be adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. 360j(g),” the letter says. “Additionally, the same device appears to be misbranded under section 502(o) the Act, 21 U.S.C. 352(o), because notice or other information respecting the device was not provided to FDA, as required by section 510(k) of the Act, 21 U.S.C. 360(k).”
Dr. PRP America's Marcy Rogers told Focus via email that her company does not manufacture these kits. "We purchased them initially from the manufacturer, Dr. PRP RMedica, based in Seoul who was selling them as a blood tube which in fact they are. They indicated in their promotional materials they were FDA approved as a blood tube. Their company in the US, Dr. PRP USA, is marketing these kits just as we did. We changed suppliers 12 months or longer ago to another vendor in Seoul who also has a blood tool kit and a centrifuge. All of the materials on our website came from the manufacturer...I am working with the FDA to resolve any issues and called their consumer safety officer [on Monday] upon receipt of the letter."
Letter
Editor's note: This article was updated on Tuesday, 11/29, with Rogers' comments on the letter.
Tags: Dr. PRP America, blood plasma levels, PRP Kit, centrifuge
Regulatory Focus newsletters
All the biggest regulatory news and happenings.